Jianchang Lin
Takeda (Japan)(JP)
Publications by Year
Research Areas
Statistical Methods in Clinical Trials, Lung Cancer Treatments and Mutations, Optimal Experimental Design Methods, Health Systems, Economic Evaluations, Quality of Life, Advanced Causal Inference Techniques
Most-Cited Works
- → Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma(2016)1,044 cited
- → Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer(2021)285 cited
- → Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial(2021)220 cited
- → Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients(2017)111 cited
- → Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)(2015)69 cited
- → Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials(2017)66 cited
- → Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma(2017)59 cited
- → Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data(2021)55 cited
- → Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1(2017)54 cited
- → Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations(2023)46 cited